Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Myriad Genetics (MYGN)
NASDAQ:MYGN
Myriad Genetics (MYGN) Stock Price & Analysis
344 Followers
MYGN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$13.82 - $25.95
Previous Close$22.76
Volume597.43K
Average Volume (3M)716.53K
Market Cap
$2.06B
Enterprise Value$2.07B
Total Cash (Recent Filing)$140.90M
Total Debt (Recent Filing)$152.10M
Price to Earnings (P/E)―
Beta2.32
Next Earnings
Aug 01, 2024EPS Estimate
-$0.01Last Dividend Ex-Date
Jun 15, 2009Dividend YieldN/A
Share Statistics
EPS (TTM)-2.82
Shares Outstanding90,507,981
10 Day Avg. Volume549,819
30 Day Avg. Volume716,531
Standard Deviation0.16
R-Squared0.41
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)13.89
Price to Sales (P/S)2.73
Price to Cash Flow (P/CF)-9.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.75
Enterprise Value/Gross Profit4.01
Enterprise Value/Ebitda-12.01
Forecast
1Y Price Target
$31.50Price Target Upside38.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Myriad Genetics News
Bulls Say, Bears Say
Bulls Say
Analyst UpgradeMyriad Genetics is upgraded to Outperform from Market Perform with a raised price target to $35, reflecting a positive outlook on the company's financial performance.
Profitability ForecastAnalysts expect a return to positive EPS of $0.04 this year and $0.34 in 2025, indicating an improvement in the company's profitability.
Revenue GrowthThe company has consistently beaten consensus revenue estimates in 9 of the past 12 quarters, demonstrating strong and reliable financial growth.
Bears Say
Growth SustainabilityAnalyst concerns over the sustainability of growth and profitability amid new entries in competitive markets could dampen investor confidence.
ProfitabilityAdjusted gross margins falling short of expectations suggest the company is facing profitability pressures.
Revenue ConcernsHCT revenue not meeting expectations implies that certain areas of the business might be underperforming.
---
Ownership Overview
7.69% Insiders
24.49% Mutual Funds
55.01% Other Institutional Investors
12.81% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MYGN FAQ
What was Myriad Genetics’s price range in the past 12 months?
Myriad Genetics lowest stock price was $13.82 and its highest was $25.95 in the past 12 months.
What is Myriad Genetics’s market cap?
Currently, no data Available
When is Myriad Genetics’s upcoming earnings report date?
Myriad Genetics’s upcoming earnings report date is Aug 01, 2024 which is in 61 days.
How were Myriad Genetics’s earnings last quarter?
Myriad Genetics released its earnings results on May 07, 2024. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.104 by $0.094.
Is Myriad Genetics overvalued?
According to Wall Street analysts Myriad Genetics’s price is currently Undervalued.
Does Myriad Genetics pay dividends?
Myriad Genetics pays a Notavailable dividend of $1.75 which represents an annual dividend yield of N/A. See more information on Myriad Genetics dividends here
What is Myriad Genetics’s EPS estimate?
Myriad Genetics’s EPS estimate is -$0.01.
How many shares outstanding does Myriad Genetics have?
Myriad Genetics has 90,507,980 shares outstanding.
What happened to Myriad Genetics’s price movement after its last earnings report?
Myriad Genetics reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.104. Following the earnings report the stock price went up 21.082%.
Which hedge fund is a major shareholder of Myriad Genetics?
Among the largest hedge funds holding Myriad Genetics’s share is Glenview Capital Management LLC. It holds Myriad Genetics’s shares valued at 105M.
---
Myriad Genetics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$31.50 (38.40% Upside)
$31.50 (38.40% Upside)
Blogger Sentiment
Bullish
MYGN Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 112.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.9M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.17%
12-Months-Change
Fundamentals
Return on Equity
-29.41%
Trailing 12-Months
Asset Growth
-5.03%
Trailing 12-Months
Company Description
Myriad Genetics
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to asses an individual's risk of developing a disease later in life. The Other segment offers products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients; and also includes corporate services such as finance, human resources, legal, and information technology. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.
---
MYGN Company Deck
---
MYGN Earnings Call
Q1 2024
0:00 / 0:00
---
MYGN Stock 12 Month Forecast
Average Price Target
$31.50
▲(38.40% Upside)
Technical Analysis
Best Analysts Covering MYGN
1 Year
1 Year Success Rate
5/7 ratings generated profit
1 Year Average Return
+8.67%
reiterated a buy rating 4 months ago
Copying Matthew Sykes's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +8.67% per trade.
---